
Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Anton Porsteinsson, MD, discusses some specifics for fine-tuning the care of patients with Alzheimer disease. Here: optimizing physical health and mental stimulation and promoting a brain-healthy diet and aerobic exercise.
Anton Porsteinsson, MD, discusses some specifics for fine-tuning the care of patients with Alzheimer disease. Here: optimizing physical health and mental stimulation and promoting a brain healthy diet and aerobic exercise.